“I expect some of these, some of these share losses here that we've seen in The U. S. To impact our growth rate here. And The US pediatric for the next couple of quarters.”

In context

“defending the use of it going forward. I think your other comment was pockets of softness in in nutrition. I'd say for me, think if you look at the 4% growth, it's pretty much in line with our kinda historical growth rate. I think the one that was a little bit off where we historically had been was in our U. S. Pediatric And that's just competitive competitive impact. We gave back some share, that we had captured last year when a competitor experienced a supply disruption. I knew it was going to be difficult to hold on to it, to hold on to it permanently. But still, I'm disappointed, that we saw that happen. And then on top of that, we also saw, a large WIC contract, state contract move from Abbott Laboratories to a competitor in in the quarter. So that so that had an impact over there. I I expect some of these, some of these share losses here that we've seen in The U. S. To impact our growth rate here. And The US pediatric for the next couple of quarters. But what I'll say is we faced this during the supply disruption in 2022 and we got our share back. It takes a few quarters but I'm, I'm, I'm very confident the team will be able to do that. First, because we we recently won two new WIC contracts The combination of those two contracts actually are higher than the one that we lost, but those go into into effect Q1 and Q2 Of Next Year. And Then We've Got Several New Product Launches That We'll Be Launching Here In The US, over the next couple of quarters. So it's gonna take a couple of quarters, but I'm I'm confident we'll be able to get our share back. Thank you. Robert Ford: Thank you. Operator: Our next question comes from Travis Steed from BofA Securities. Your line is open. Travis Steed: Hey, thanks for the question. I guess kind of big”